

RN 396718-71-1 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-[(10-aminodecyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396718-75-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 396718-77-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]butyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 396718-79-9 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 396718-81-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[8-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]octyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 396718-83-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[10-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]decyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 40 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:193332 HCAPLUS
DOCUMENT NUMBER: 110:193332
TITLE: Preparation of adenosine-5'-carboxamide derivatives as adenosine-2 receptor agonists, antipsychotics, and antihypertensives and pharmaceutical compositions containing them
INVENTOR(S): Hutchison, Alan J.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 277917	A2	19880810	EP 1988-810050	19880129
EP 277917	A3	19900328		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
FI 8800405	A	19880805	FI 1988-405	19880129	
JP 63201196	A2	19880819	JP 1988-21410	19880202	
DD 284679	A5	19901121	DD 1988-312611	19880202	
DK 8800544	A	19880805	DK 1988-544	19880203	
NO 8800469	A	19880805	NO 1988-469	19880203	
AU 8811233	A1	19880818	AU 1988-11233	19880203	
HU 46334	A2	19881028	HU 1988-509	19880203	
HU 199155	B	19900129			
ZA 8800755	A	19891025	ZA 1988-755	19880203	
PRIORITY APPLN. INFO.:			US 1987-11169	19870204	
OTHER SOURCE(S):		MARPAT 110:193332			

GI



I

AB The title compds. [I; R2 = H, alkyl, aralkyl; R3 = H, OH; R5 = NRR1 where R = H, alkyl and R1 = cycloalkyl, cycloalkylalkyl, 2-norbornanyl, etc.; R6 = R4NHCO where R4 = H, alkyl, aralkyl, cycloalkyl, hydroxyalkyl] (II) and their pharmaceutically acceptable salts, useful as adenosine-2 receptor agonists, antipsychotics, antithrombotics, and antihypertensives, are prepd. A mixt. of 2-chloro-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide and 2-phenethylamine was heated at 130.degree. for 2 h to give 2-(2-phenethylamino)-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide, which was heated with 1N HCl at 65.degree. for 1 h to give 2-(2-phenethylamino)-5'-N-ethylcarboxamide (III). In vivo studies of the adenosine-2 receptor agonistic activity of II using spontaneously hypertensive rats showed that II effectively lowered the blood pressure without any significant effect on the heart rate. One thousand tablets were prepd. from III 100.00, lactose 2400.00, corn starch 125.00, polyethyleneglycol 6000 150.00, Mg stearate 40.00 g, and water q.s.

IT **120225-76-5P 120225-77-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of adenosinecarboxamide derivs. as CNS and cardiovascular agents)

RN 120225-76-5 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 120225-77-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(2-phenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **120225-75-4 120225-76-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of adenosinecarboxamide derivs. as CNS and cardiovascular agents)

RN 120225-75-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-chloro-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 120225-76-5 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—OBu-t

L35 ANSWER 41 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:24223 HCAPLUS
DOCUMENT NUMBER: 110:24223
TITLE: Conformational analysis of 8-substituted isopropylidene derivatives of adenosine-5'-carboxylic acid
AUTHOR(S): Timoshchuk, V. A.; Ermolenko, T. M.; Akhrem, A. A.
CORPORATE SOURCE: Beloruss. Inst. Epidemiol. Mikrobiol., Minsk, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1988), 24(6), 1214-20
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB NMR data confirms that for 2',3'-O-isopropylidene derivs. of adenosine 5'-carboxylic acid the most probable conformation is C4'-endo, O4'-exo, and C1'-endo. Compds. of this series are characterized principally by a syn-conformation of the heterocycle around the N-glycosidic bond relative to the ribose fragment of the mols. CD data confirmed that conformations are stabilized by a spatial convergence of the N3 heterocyclic atom and the carboxyl group.

IT **101966-36-3 101966-40-9 101966-46-5**
RL: PRP (Properties)
(conformation of, NMR and CD in relation to)

RN 101966-36-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-(6,8-diamino-9H-purin-9-yl)-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 101966-40-9 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(methylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 101966-46-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(dimethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 42 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:627200 HCAPLUS
DOCUMENT NUMBER: 105:227200
TITLE: Synthesis of uronic acid nucleosides. II. Synthesis of 8-substituted adenosine-5'-carboxamides
AUTHOR(S): Akhrem, A. A.; Ermolenko, T. M.; Timoshchuk, V. A.
CORPORATE SOURCE: Beloruss. Nauchno-Issled. Inst. Epidemiol. Mikrobiol., Minsk, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1985), 21(8), 1800-5
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I

AB Amides of 8-substituted adenosine-5'-carboxylic acid were prepd. Starting from the Me ester of 8-bromo-2',3'-O-isopropylideneadenosine-5'-carboxylate and the Et ester of 8-bromoadenosine-5'-carboxylate were obtained the amide, methylamide, dimethylamide, and the ethylamide of the corresponding acid, which contained bromo-, amino, methylamino-, dimethylamino-, ethylamino-, and mercapto groups in position 8 of the adenine base. Thus, treating adenosine I (R = OMe, X = Br) with NH3 in MeOH at 18-25.degree. gave 82% I (R = NH2, X = Br). The selectivity of primary and secondary amines, on the ester group and 8-bromoadenine residue was demonstrated.

IT **101966-40-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

RN 101966-40-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(methylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **101966-36-3P 101966-46-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 101966-36-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-(6,8-diamino-9H-purin-9-yl)-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 101966-46-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(dimethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 43 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:56841 HCAPLUS
DOCUMENT NUMBER: 100:56841
TITLE: Fibrinolytic formulations containing adenosine derivatives
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 58174324 A2 19831013 JP 1982-58507 19820407
PRIORITY APPLN. INFO.: JP 1982-58507 19820407
GI



I

AB Formulations contg. I (R1 and R2 = propionyl or R1 + R2= methoxyethylidene) activate fibrinolysis. Thus, 2',3'-O-dipropionyladenosine-5'-carboxylic acid butylamide(I) [88480-43-7] 70, D-mannitol 73, and corn starch 50 g were mixed using 5 g hydroxypropyl cellulose as binder, granulated, combined with 2 g Mg stearate, and made into tablets. I was prepd. by the acylation of adenosine-5'-carboxylic acid butylamide [35788-23-9] with propionic anhydride.

IT **62622-82-6P**
RL: PREP (Preparation)
(prepn. of, for fibrinolysis activation)

RN 62622-82-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-N-butyl-1-deoxy-2,3-O-(1-methoxyethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 44 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:26035 HCAPLUS
DOCUMENT NUMBER: 100:26035
TITLE: Fibrinolytic formulations containing adenosine derivatives
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58174323	A2	19831013	JP 1982-58506	19820407

PRIORITY APPLN. INFO.: JP 1982-58506 19820407
GI



I

AB Fibrinolytic formulations contain I (R1 and R2 = H, alkanoyl, etc.; R3 = C1-3 alkylamino, alkenylamino, etc.). Thus, adenosine-5'-carboxylic acid cyclohexylamide [35788-32-0] was treated with Me orthoacetate [56893-90-4] to give 2',3'-O-methoxyethylideneadenosine-5'-carboxylic acid cyclohexylamide (II) [88255-85-0]. Tablets contg. 1% I were described. The min. effective oral dose for the hemolytic activity of II in rats was 30 mg/kg.

IT **62622-78-0P 88255-90-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and fibrinolytic activity of)

RN 62622-78-0 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methoxyethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 88255-90-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methoxyethylidene)-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 45 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1980:215696 HCAPLUS
DOCUMENT NUMBER: 92:215696
TITLE: N1,N6-Ethenoadenosine-5'-(N-ethyl carboxamide)
AUTHOR(S): Prasad, Raj Nandan; Tietje, Karin
CORPORATE SOURCE: Org. Chem. Res., Abbott Lab., Ltd., Montreal, QC, H4P 1A5, Can.
SOURCE: Nucl. Acid Chem. (1978), Volume 2, 701-7. Editor(s): Townsend, Leroy B.; Tipson, R. Stuart. Wiley: New York, N. Y.
CODEN: 42TBAU
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I II III

AB Ethenoadenosine I was prepd. by cyclization of adenosine II with ClCH2CHO. II was prepd. from acid III by 3 methods, e.g., by sequential chlorination with SOCl2, amidation with EtNH2, and deisopropylidenation.

IT **39491-53-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deisopropylidenation of)

RN 39491-53-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 60 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	1976:59956 HCAPLUS
DOCUMENT NUMBER:	84:59956
TITLE:	Adenosine-5'-carboxylic acid amides
INVENTOR(S):	Stein, Herman Hal; Prasad, Raj N.
PATENT ASSIGNEE(S):	Abbott Laboratories, USA
SOURCE:	U.S., 7 pp. Division of U.S. 3,864,483. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3914415	A	19751021	US 1974-492950	19740730
US 4029884	A	19770614	US 1972-236980	19720322
US 3864483	A	19750204	US 1973-370084	19730614

PRIORITY APPLN. INFO.: US 1971-125893 19710318
US 1972-236980 19720322
US 1973-370084 19730614

GI For diagram(s), see printed CA Issue.

AB I (e.g., R1 = H, R2 = H, adamantyl, cyclopropyl, Et, PhOCH2CH2, allyl, 2,6-Me2C6H3, HOCH2CH2; R1 = R2 = allyl) (34 compds.), possessing cardiovascular and antiinflammatory activities, were prepd. by treatment of 2',3'-O-isopropylideneadenosine-5'-carboxylic acid chloride with R1R2NH followed by hydrolysis with 1N HCl.

IT **39491-51-5P 39491-53-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)

RN 39491-51-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39491-53-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **58048-27-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 58048-27-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 61 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:44606 HCAPLUS
DOCUMENT NUMBER: 84:44606
TITLE: Compounds for increasing coronary partial pressure of oxygen in mammals
INVENTOR(S): Stein, Herman Hal; Prasad, Raj N.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 7 pp. Division of U.S. 3,864,483.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 3914414	A	19751021	US 1974-492949	19740730
US 4029884	A	19770614	US 1972-236980	19720322
US 3864483	A	19750204	US 1973-370084	19730614
US 3966917	A	19760629	US 1975-590548	19750626

PRIORITY APPLN. INFO.:
US 1971-125893 19710318
US 1972-236980 19720322
US 1973-370084 19730614
US 1974-492949 19740730

AB Adenosine-5'-carboxamides, useful as antihypertensive agents, were prepd. by treating 2',3'-O-isopropylideneadenosine-5'-carbonyl chloride (I) with amines followed by acid hydrolysis. Thus, I with NH3 2 hr at -50.degree. gave 55% 2',3'-O-isopropylideneadenosine-5'-carboxamide (II). Treatment of II with 1N HCl at 60-70.degree. for 45 min gave adenosine-5'-carboxamide.

IT **57872-94-3P 57872-95-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antihypertensive activity of)

RN 57872-94-3 HCAPLUS
RN 57872-95-4 HCAPLUS

L35 ANSWER 62 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1975:156656 HCAPLUS
DOCUMENT NUMBER: 82:156656
TITLE: 1,N6-Etheno-5'-adenosine carboxamides
INVENTOR(S): Prasad, Raj N.; Garmaise, David L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3830796	A	19740820	US 1972-317326	19721221
US 3931401	A	19760106	US 1974-472029	19740521

PRIORITY APPLN. INFO.: US 1972-317326 19721021

GI For diagram(s), see printed CA Issue.

AB Adenosines (I; R = Et, allyl, cyclobutyl), useful as antianginals and antihypertensives, were prepd. Thus, 2',3'-O-isopropylideneadenosine 5'-carboxylic acid chloride was treated with EtNH2 at -50 to -35.degree. to give the 5'-(N-ethylcarboxamide) which, treated 1 hr with 1N HCl, gave adenosine 5'-(N-ethylcarboxamide) II. Treatment of II with ClCH2CHO gave I (R = Et). The allyl and cyclobutyl derivs. were similarly prepd.

IT **39491-53-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 39491-53-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 63 OF 63 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1973:16454 HCAPLUS
DOCUMENT NUMBER: 78:16454
TITLE: Adenosine-5'-carboxamides
INVENTOR(S): Stein, Herman Hal; Prasad, Raj Nandan
PATENT ASSIGNEE(S): Abbott Laboratories
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2213180	A	19720928	DE 1972-2213180	19720317
CA 1019727	A1	19771025	CA 1972-135283	19720222
GB 1386656	A	19750312	GB 1972-8446	19720223
ZA 7201222	A	19721129	ZA 1972-1222	19720224
CH 551446	A	19740715	CH 1972-3873	19720316
FR 2130364	A5	19721103	FR 1972-9349	19720317
SE 405363	C	19790315	SE 1972-3515	19720317
SE 405363	B	19781204		

PRIORITY APPLN. INFO.: US 1971-125893 19710318
GI For diagram(s), see printed CA Issue.
AB Four title compds. (I, R = H; R1 = NH2, NHMe, NMe2, and NHEt), useful in the treatment of angina pectoris and circulatory disturbances and as antihypertensives, were prepd. Chlorination of I (RR = CMe2, R1 = OH) with SOCl2 to give I (RR = CMe2, R1 = Cl), followed by treatment with amines, R1H, and hydrolysis with N HCl gave the corresponding title compd.
IT **39491-51-5P 39491-53-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 39491-51-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39491-53-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d que l21
L1 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L2 3214 SEA FILE=REGISTRY SSS FUL L1
L20 STR



NODE ATTRIBUTES:
CONNECT IS E2 RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 36

STEREO ATTRIBUTES: NONE
L21 0 SEA FILE=REGISTRY SUB=L2 SSS FUL L20

=> d que l29
L1 STR



NODE ATTRIBUTES:
NSPEC IS RC AT 18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L2	3214	SEA	FILE=REGISTRY SSS FUL L1
L22	36416	SEA	FILE=HCAPLUS ABB=ON PLU=ON HYPERTENSION/CT
L25	5576	SEA	FILE=HCAPLUS ABB=ON PLU=ON ISCHEMIA+OLD/CT
L26	2613	SEA	FILE=HCAPLUS ABB=ON PLU=ON ANTI-ISCHEMIC AGENTS/CT
L27	4987	SEA	FILE=HCAPLUS ABB=ON PLU=ON VASODILATION/CT
L28	8845	SEA	FILE=HCAPLUS ABB=ON PLU=ON VASODILATORS/CT
L29	39	SEA	FILE=HCAPLUS ABB=ON PLU=ON L2 AND (L22 OR HYPERTENS? OR L25 OR L26 OR ISCHEM? OR L27 OR L28 OR VASODIL? OR SYMPATHET?(2A)BLOCK? OR PROPHYLACT?)

=> d ibib abs hitstr l29 1-39

L29 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:332678 HCAPLUS
DOCUMENT NUMBER: 136:350561
TITLE: Use of P2Y12 receptor antagonists as platelet aggregation inhibitors
INVENTOR(S): Boyer, Jose L.; Olins, Gillian M.; Yerxa, Benjamin R.; Douglass, James G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U. S. Ser. No. 643,138.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052337	A1	20020502	US 2001-934970	20010821
US 2002128224	A1	20020912	US 2002-87551	20020227
US 2003008834	A1	20030109	US 2002-82998	20020227

PRIORITY APPLN. INFO.: US 2000-643138 A2 20000821
US 2001-934970 A2 20010821

OTHER SOURCE(S): MARPAT 136:350561

AB The invention discloses a method of preventing or treating diseases or conditions assocd. with platelet aggregation and treating thrombosis. The method involves administering to a subject a pharmaceutical compn. comprising a therapeutic effective amt. of P2Y12 receptor antagonist compd., to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compds. disclosed include mononucleoside polyphosphates and dinucleoside polyphosphates.

IT **401619-32-7 401619-52-1 401619-57-6**
401620-06-2 420131-31-3 420131-40-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(P2Y12 receptor antagonists, as platelet aggregation inhibitors)

RN 401619-32-7 HCAPLUS

CN Adenosine 5'-(trihydrogen diphosphate), 2',3'-O-(2-phenylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401619-52-1 HCAPLUS

CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)- , P'''.fwdarw.5'-ester with uridine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 401619-57-6 HCAPLUS
CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)-, P'''.fwdarw.5'-ester with 2',3'-O-(2-phenylethylidene)uridine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Ph

PAGE 2-A

RN 401620-06-2 HCAPLUS
CN Adenosine, N-[2-(methylthio)ethyl]-2',3'-O-(2-phenylethylidene)-2-[(3,3,3-trifluoropropyl)thio]-, 5'-[hydrogen (difluorophosphonomethyl)phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 420131-31-3 HCAPLUS
CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)-, P'''.fwdarw.5'-ester with adenosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 420131-40-4 HCAPLUS
CN Adenosine 5'-(pentahydrogen tetraphosphate), N-[2-(methylthio)ethyl]-2',3'-O-(2-phenylethylidene)-2-[(3,3,3-trifluoropropyl)thio]-, P'''.fwdarw.5'-ester with 2',3'-O-(2-phenylethylidene)adenosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L29 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:271942 HCAPLUS
DOCUMENT NUMBER: 136:291358
TITLE: Diagnostic uses of 2-substituted adenosine carboxamides
INVENTOR(S): Leung, Edward
PATENT ASSIGNEE(S): King Pharmaceuticals Research and Development, Inc., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6368573	B1	20020409	US 1999-440330	19991115

PRIORITY APPLN. INFO.: US 1999-440330 19991115
OTHER SOURCE(S): MARPAT 136:291358

AB The invention concerns a method for measuring myocardial function in a mammal in need of such measurement by: (a) administering 2-substituted adenosine carboxamide derivs. at a dosage rate of less than 1 .mu.g/kg/min, preferably between about 0.01 and 1 .mu.g/kg/min; and then: (b) performing a technique on the mammal to detect myocardial function. The method can be used to diagnose myocardial dysfunction by electrophysiol. anal. or by imaging the vasculature of the heart, esp. under conditions that simulate stress.

IT **120225-76-5**
RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(diagnostic uses of 2-substituted adenosine carboxamides)

RN 120225-76-5 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:904207 HCAPLUS
DOCUMENT NUMBER: 136:37902
TITLE: Preparation of 2-aminocarbonyl-9H-purine nucleosides and their uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents
INVENTOR(S): Mantell, Simon John; Stephenson, Peter Thomas
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094368	A1	20011213	WO 2001-IB973	20010605

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002058641	A1	20020516	US 2001-874007	20010605
EP 1292604	A1	20030319	EP 2001-934242	20010605

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	GB 2000-14048	A 20000606
	GB 2000-18246	A 20000725
	GB 2000-24920	A 20001011
	US 2000-214307P	P 20000627
	US 2000-225236P	P 20000815
	US 2000-245243P	P 20001102
	WO 2001-IB973	W 20010605

OTHER SOURCE(S): MARPAT 136:37902
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 2-Aminocarbonyl-9H-purine nucleosides I wherein R, R2 are independently H, alkyl; R1 is H, substituted alkyl, fluorenyl; R3 is H, alkyl, cycloalkyl, benzyl; R4 is substituted azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; R3R4 taken together with the nitrogen atom to which they are attached, represent azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by alkyl or cycloalkyl; R5 is CH2OH, amide; X is substituted alkylene; RX or R2X with the nitrogen atom to which they are attached , represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; Y is CO, CS, SO2, C=N(CN); were prepd. as A2a receptor agonists and anti-inflammatory agents. Thus, nucleoside II was prepd. and tested as A2a receptor agonist and anti-inflammatory agent. Title compds. were tested for biol. activity as A2a receptor agonists and anti-inflammatory agents and all were found to have an IC50 of less than 100 nM.

IT **380222-88-8P 380222-90-2P 380222-92-4P**
380222-93-5P 380222-94-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 2-aminocarbonyl-9H-purine nucleosides and uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents)

RN 380222-88-8 HCAPLUS

CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380222-90-2 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-(ethoxycarbonyl)-9H-purin-9-yl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380222-92-4 HCAPLUS
CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380222-93-5 HCAPLUS
CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380222-94-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]amino]carbonyl]-9H-purin-9-yl]-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:911265 HCAPLUS
DOCUMENT NUMBER: 134:66148
TITLE: Induction of pharmacological stress with alkynyladenosine A2A adenosine receptor agonists
INVENTOR(S): Linden, Joel M.; Glover, David K.; Beller, George A.; MacDonald, Timothy
PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078774	A2	20001228	WO 2000-US16029	20000612
WO 2000078774	A3	20010712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011725	A	20020326	BR 2000-11725	20000612
EP 1194440	A2	20020410	EP 2000-941335	20000612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003502433	T2	20030121	JP 2001-504939	20000612
NO 2001005974	A	20020214	NO 2001-5974	20011206

PRIORITY APPLN. INFO.: US 1999-336198 A 19990618
WO 2000-US16029 W 20000612

OTHER SOURCE(S): MARPAT 134:66148

AB A method is provided employing alkynyladenosine A2A adenosine receptor agonists as **vasodilators** to detect the presence and assess the severity of coronary artery stenosis. Prepn. of alkynyladenosine derivs. is also described.

IT **141018-25-9P 141018-26-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; alkynyladenosine A2A adenosine receptor agonist for induction of pharmacol. stress and diagnosis of coronary artery stenosis)

RN 141018-25-9 HCAPLUS
CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141018-26-0 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:34074 HCAPLUS
DOCUMENT NUMBER: 128:188277

TITLE: Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA

AUTHOR(S): Camaioni, Emidio; Di Francesco, Emanuela; Vittori, Sauro; Volpini, Rosaria; Cristalli, Gloria

CORPORATE SOURCE: Dipartimento di Scienze Chimiche, Universita di Camerino, Camerino, 62032, Italy

SOURCE: Bioorganic & Medicinal Chemistry (1997), 5(12), 2267-2275
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Among the recently reported 2-(ar)alkynyl derivs. of 5'-N-ethylcarboxamidoadenosine (NECA), the (R,S)-2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA [(R,S)-PHPNECA or SCH 59761] was found to be a very potent agonist at A1 and A2A receptor subtypes, with a Ki of 2.5 nM and 0.9 nM, resp. Furthermore, this compd. showed an inhibitory activity on platelet aggregation 16-fold higher than NECA, being the most potent anti-aggregatory nucleoside reported so far. Since this compd. bears a chiral carbon in the side chain, the diastereoisomer sepn. was undertaken both by chiral HPLC and by a stereospecific synthetic method. Binding assays have shown that the (S)-diastereomer is about fivefold more potent and selective than the (R)-diastereomer as agonist of the A2A receptor subtype [(S)-PHPNECA, KiA2A = 0.5 nM; (R)-PHPNECA, KiA2A = 2.6 nM]. Functional studies indicated that (S)-PHPNECA possesses marked **vasodilating** activity and produces a relevant decrease in heart rate. Moreover, the (S)-diastereomer proved to be about ten times more potent than the (R)-diastereomer in inducing cardiovascular effects, in in vivo hemodynamic studies. However, the greatest difference between these two enantiomers resulted in the platelet aggregation test: in fact, the (R)-diastereomer displayed an inhibitory activity similar to that of NECA, whereas the (S)-diastereomer was 37-fold more active than NECA as an inhibitor of rabbit platelet aggregation, induced by ADP. These data suggest that (S)-PHPNECA could be a useful tool to investigate the mode of binding of agonists to the platelet adenosine receptor subtype.

IT **203794-22-3P 203794-23-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. evaluation of diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor agonists)

RN 203794-22-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(3S)-3-[[[[(1R)-1-(1-naphthalenyl)ethyl]amino]carbonyl]oxy]-3-phenyl-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 203794-23-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(3R)-3-[[[[(1R)-1-(1-naphthalenyl)ethyl]amino]carbonyl]oxy]-3-phenyl-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT **162936-24-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and biol. evaluation of diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor agonists)
RN 162936-24-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **203794-21-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. evaluation of diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor agonists)
RN 203794-21-2 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(3-hydroxy-3-phenyl-1-propynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:761605 HCAPLUS
DOCUMENT NUMBER: 128:34983
TITLE: Preparation of nucleosides as A3 adenosine receptor agonists
INVENTOR(S): Jacobson, Kenneth A.; Jeong, Heaok Kim; Siddiqi, Suhaib M.; Johnson, Carl R.; Secrist, John A., III; Tiwari, Kamal N.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 274,628. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5688774	A	19971118	US 1995-396111	19950228
US 5773423	A	19980630	US 1994-274628	19940713

PRIORITY APPLN. INFO.: US 1993-91109 B2 19930713
US 1993-163324 B2 19931206
US 1994-274628 A2 19940713

OTHER SOURCE(S): MARPAT 128:34983
GI



AB Title nucleosides I (R = H, Y; R1 = benzyl, halobenzyl; R2 = H, halo, alkylamino; X1 = H, alkyl; X2 = alkylamido; X3, X4 = independently H, OH,

NH2, N3, halo, Bz) were prepd. as A3 adenosine receptor agonists. The present invention also provides a method of selectively activating an A3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A3 adenosine receptor a therapeutically or **prophylactically** effective amt. of a compd. which binds with the A3 receptor so as to stimulate an A3 receptor-dependent response. Thus, N3-(3-iodobenzyl)-9-Me adenine was prepd. and showed an affinity at rat brain adenosine receptors (Ki = 2.23-48.3 .mu.M).

IT **163042-89-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nucleosides as a adenosine receptor agonists)

RN 163042-89-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **170966-20-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of nucleosides as a adenosine receptor agonists)

RN 170966-20-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[[(3-aminophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:12370 HCAPLUS
DOCUMENT NUMBER: 126:75189
TITLE: Preparation of N6-(phenylalkyl)adenosine derivatives having selective affinity to adenosine A3 receptor
INVENTOR(S): Mitsuya, Morihiro; Takeshita, Hiroshi; Ihara, Masaki
PATENT ASSIGNEE(S): Banyu Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08269083	A2	19961015	JP 1995-101772	19950403

PRIORITY APPLN. INFO.: JP 1995-101772 19950403
OTHER SOURCE(S): MARPAT 126:75189
GI



I

AB The title compds. (I; Ar = Ph, arom. heterocyclyl; Q = lower alkylene; R1 = Cl, lower alkyl, alkoxy, or alkylthio, NR4R5; wherein R4 , R5 = H, lower alkyl; R2 = HOCH2, H2NCO, N-alkylcarbamoyl; R3 = H, OH, NH2, lower alkoxy) or pharmaceutically acceptable salts thereof, which have reduced side effects, are prepd. A remedy for **hypertension**, unstable angina pectoris, acute myocardial infarction, and/or brain nerve disorders contg. I is claimed. Thus, 1-(2,6-dichloro-9H-purin-9-yl)-2,3-O-isopropylidene-.beta.-D-ribofuranuronic acid (prepn. given) was condensed with 3-(2-thiazolyl)benzylamine hydrochloride (prepn. given) in EtOH at room temp. for 15 h and then with methylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CHCl3, followed by treatment with aq. 85% HCO2H, to give the title compd. (II). II showed Ki (competitive binding inhibition const.) of 6,990 and 1.00 for adenosine A1 receptor prepn. from rat homogenized brain and adenosine A3 receptor of Rat basophilic leukemia mast cells (RBL-2H3), resp.

IT **184847-93-6P 184847-94-7P 184847-95-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N6-(phenylalkyl)adenosine derivs. having selective affinity to adenosine A3 receptor for disease treatment)

RN 184847-93-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[2-chloro-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184847-94-7 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-[2-chloro-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 184847-95-8 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-methyl-1-[2-(methylamino)-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:616599 HCAPLUS
DOCUMENT NUMBER: 125:317355
TITLE: Preparation of adenosine derivatives having antihypertensive, cardioprotective, anti-**ischemic** and antilipolytic properties
INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: U.S., 27 pp., Cont.-in-part of U. S. Ser. No. 229,882, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5561134	A	19961001	US 1994-316761	19941003
US 5364862	A	19941115	US 1992-955783	19921002
CA 2188147	AA	19951026	CA 1995-2188147	19950419
CA 2188147	C	20010403		
WO 9528160	A1	19951026	WO 1995-US4800	19950419
W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9522949	A1	19951110	AU 1995-22949	19950419

AU 684635	B2	19971218			
EP 758897	A1	19970226	EP 1995-916451	19950419	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1148811	A	19970430	CN 1995-193170	19950419	
CN 1086704	B	20020626			
HU 75331	A2	19970528	HU 1996-2829	19950419	
BR 9507327	A	19971007	BR 1995-7327	19950419	
JP 09512020	T2	19971202	JP 1995-527171	19950419	
EP 1006115	A2	20000607	EP 2000-103467	19950419	
EP 1006115	A3	20000628			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE					
RU 2166319	C2	20010510	RU 1996-121567	19950419	
NZ 284357	A	20010629	NZ 1995-284357	19950419	
CZ 289528	B6	20020213	CZ 1996-3032	19950419	
PL 182942	B1	20020531	PL 1995-316961	19950419	
US 5736554	A	19980407	US 1995-455361	19950531	
US 5652366	A	19970729	US 1995-484811	19950607	
NO 9604438	A	19961018	NO 1996-4438	19961018	
FI 9604218	A	19961217	FI 1996-4218	19961018	
CZ 290897	B6	20021113	CZ 2001-2885	20010808	

PRIORITY APPLN. INFO.:	US 1990-587884	B2	19900925
	US 1992-955783	A2	19921002
	US 1994-229882	B2	19940419
	US 1994-316761	A	19941003
	CZ 1996-3032	A3	19950419
	EP 1995-916451	A3	19950419
	WO 1995-US4800	W	19950419

OTHER SOURCE(S): MARPAT 125:317355

GI



I

AB The adenosine derivs. I [K = N or NO; Q = CH2 or O; T = R1R2NCO or R3OCH2 ; X = (un)substituted alkylene, cycloalkylene or cycloalkenylene Y = NR4, O or S; a = 0 or 1; Z = substituted pyrrolyl, pyrazolyl, indolyl, etc.; R1-5 = H, alkyl, aryl or heterocyclyl; R5,R6 = H, alkyl, aralkyl, etc.] are prepd. as antihypertensive, cardioprotective, antiischemic, and antilipolytic agents.

IT **165115-09-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate in prepn. of adenosine deriv. drug)
RN 165115-09-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:997439 HCAPLUS
DOCUMENT NUMBER: 124:202956
TITLE: Preparation of adenosine derivatives having antihypertensive, cardioprotective, anti-**ischemic** and antilipolytic properties.
INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9528160	A1	19951026	WO 1995-US4800	19950419
W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5561134	A	19961001	US 1994-316761	19941003
AU 9522949	A1	19951110	AU 1995-22949	19950419
AU 684635	B2	19971218		

EP 758897	A1	19970226	EP 1995-916451		19950419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
BR 9507327	A	19971007	BR 1995-7327		19950419
JP 09512020	T2	19971202	JP 1995-527171		19950419
RU 2166319	C2	20010510	RU 1996-121567		19950419
NZ 284357	A	20010629	NZ 1995-284357		19950419
PL 182942	B1	20020531	PL 1995-316961		19950419
NO 9604438	A	19961018	NO 1996-4438		19961018
FI 9604218	A	19961217	FI 1996-4218		19961018
PRIORITY APPLN. INFO.:			US 1994-229882	A	19940419
			US 1994-316761	A	19941003
			US 1990-587884	B2	19900925
			US 1992-955783	A2	19921002
			WO 1995-US4800	W	19950419

OTHER SOURCE(S): MARPAT 124:202956

GI



I





AB Title compds. [I; K = N, NO, CH; Q = CH2, O; T = R3R4NCO, R5OCH2; X = (substituted) alkylene, cycloalkylene, cycloalkenylene; Y = NR6, O, S; a = 0, 1; R1, R2 = H, alkyl, aralkyl, carbamoyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl; R1R2 = CO, CS, etc.; R3-R8 = H, alkyl, aryl, heterocyclyl; Z = Q1, Q2; Z1 = N, CR7, (CH)mC5, (CH)mN; m = 1, 2; Z2 = N, NR8, O, S; n = 0, 1; R9, R10 = H, OH, alkyl, hydroxyalkyl, alkylmercapto, thioalkyl, alkoxy, amino, acyl, halo, carbamoyl, etc.], were prepd. Thus, trans-2-(2-thienyl)cyclohex-4-enylamine, 6-chloropurine, and Et3N were refluxed in EtOH to give N6-[trans-2-(2-thienyl)-cyclohex-4-enyl]adenosine. The latter bound to adenosine A1 and A2 receptors with IC50 = 1.66 nM and 55 nM, resp., and induced vasorelaxation in swine coronary artery with IC50 = 0.73 .mu.M.

IT **173935-07-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of adenosine derivs. having antihypertensive, cardioprotective, anti-**ischemic** and antilipolytic properties)
RN 173935-07-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]-, (1S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:837438 HCAPLUS
DOCUMENT NUMBER: 123:257265
TITLE: Preparation of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compounds as adenosine A3 receptor agonists.
INVENTOR(S): Jacobson, Kenneth A.; Gallo-Rodriguez, Carola; Von Galen, Philip J. M.; Von Lubitz, Dag K. J. E.; Jeong, Heaok Kim
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502604	A1	19950126	WO 1994-US7835	19940713
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9473310	A1	19950213	AU 1994-73310	19940713
EP 708781	A1	19960501	EP 1994-923445	19940713
EP 708781	B1	20011004		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

AT 206432	E	20011015	AT 1994-923445		19940713
PRIORITY APPLN. INFO.:			US 1993-91109	A	19930713
			US 1993-163324	A	19931206
			WO 1994-US7835	W	19940713

OTHER SOURCE(S): MARPAT 123:257265

GI



I

AB Title compds. [I; R1 = RaRbNCO, HORc; Ra, Rb = H, alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; RaRbN = heterocyclyl; Rc = alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; R2 = H, halo, alkyl ether residue, amino, alkylamino, alkenyl, alkynyl, thio, alkylthio; R3 = (R)- and (S)-1-phenylethyl, (substituted) PhCH2, substituted phenylethyl] and related compds., were prepd. Thus, 2-chloro-N6-(3-iodobenzyl)adenine was refluxed with hexamethyldisilazane and cat. (NH4)2SO4 to give a silyl deriv. which was refluxed with N-Me I-O-acetyl-2,3-dibenzoyl-.alpha.,.beta.-D-ribofuronamide and trimethylsilyl triflate in dichloroethane to give 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-2,3-di-O-benzoyl-.beta.-D-ribofuranosyl]adenine. The latter was stirred with NH3 in MeOH for 16 h to give 68.7% 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-.beta.-D-ribofuranosyl]adenine. This showed Ki = 0.23 nM in a radioligand binding assay at rat brain A3 receptors.

IT **362-75-4**, 2',3'-Isopropylideneadenosine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compds. as adenosine A3 receptor agonists)

RN 362-75-4 HCAPLUS

CN Adenosine, 2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **19234-66-3P 23754-29-2P 152918-54-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compds. as adenosine A3 receptor agonists)

RN 19234-66-3 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23754-29-2 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 152918-54-2 HCAPLUS
CN Benzenesulfonic acid, 4-[[[9-[N-methyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:508300 HCAPLUS
DOCUMENT NUMBER: 122:291434
TITLE: 2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5'-N-Ethyluronamide as Selective A2a Adenosine Receptor Agonists
AUTHOR(S): Cristalli, Gloria; Camaioni, Emidio; Vittori, Sauro; Volpini, Rosaria; Borea, Pier Andrea; Conti, Annamaria; Dionisotti, Silvio; Ongini, Ennio; Monopoli, Angela
CORPORATE SOURCE: Dipartimento di Scienze Chimiche, Universita di Camerino, Camerino, 62032, Italy
SOURCE: Journal of Medicinal Chemistry (1995), 38(9), 1462-72
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of new 2-aralkynyl and 2-heteroaralkynyl derivs. of 5'-(N-carboxamido)adenosine NECA, e.g. I [R = H, Ph, C6H4R1-4, 2-pyridyl, 2-furyl, 2-thiazolyl; R1 = Me, OMe, OH, NH2, F], were synthesized and studied in binding and functional assays to assess their potency for the A2a compared to A1 adenosine receptors. Compds. bearing an arom. or heteroarom. ring, conjugated to the triple bond, showed generally weaker activity at the A2a receptor and lower selectivity (A2a vs A1) than the alkylalkynyl derivs. previously reported. However, the (4-formylphenyl)ethynyl deriv. showed affinity in the low nanomolar range and high selectivity (about 160-fold) for the A2a receptor. The presence of heteroatoms improved vasorelaxant activity, I (R = 2-thiazolyl) being the most potent in the series. Introduction of methylene groups between the triple bond and the Ph ring favored the A2a binding affinity, and the 5-phenyl-1-pentynyl deriv. was found to be highly potent and selective (about 180-fold) at A2a receptors. With regard to platelet activity, the presence of arom. or heteroarom. rings decreased the potency in comparison with that of NECA and of N-ethyl-1'-deoxy-1'-(6-amino-2-hexynyl-9H-purin-9-yl)-.beta.-D-ribofuranuronamide (HENECA). Introduction of a methylene group was effective in increasing antiaggregatory potency only when this group is linked to a heteroatom. From these data and those previously reported, the structure-activity relationships derived for the 2-alkynyl-substituted ribose uronamides would indicate that selective potentiation of A2a receptor affinity could be obtained by arom. rings not conjugated with the triple bond or by heteroarom. groups. As for A2a receptors on platelets, the presence of arom. rings, either conjugated or unconjugated to the triple bond, is detrimental for the antiaggregatory activity. Some of the compds. included in this series retain interesting **vasodilating** properties and merit further investigation for their potential in the treatment of cardiovascular disorders.

IT **141018-26-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aralkynyl and heteroalkynyl derivs. of carboxamidoadenosine as selective A2a adenosine receptor agonists)

RN 141018-26-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-

2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **162936-24-5P 162936-39-2P 162936-40-5P**
162936-41-6P 162936-42-7P 162936-43-8P
162936-44-9P 162936-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aralkynyl and heteroalkynyl derivs. of carboxamidoadenosine as selective A2a adenosine receptor agonists)

RN 162936-24-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-39-2 HCAPLUS

CN Benzenepropanoic acid, 4-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-40-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(5-phenyl-1-pentynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-41-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(1H-imidazol-1-yl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-42-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(1-piperidinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-43-8 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-methyl-1-piperazinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-44-9 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-morpholinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162936-45-0 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-thiomorpholinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:346678 HCAPLUS
DOCUMENT NUMBER: 122:106395
TITLE: preparation of adenosine sulfohydrocarbon radicals for treatment of **ischemia** or hypoxia in mammals
INVENTOR(S): Jacobson, Kenneth A.; Maillard, Michel C.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402497	A1	19940203	WO 1993-US6590	19930713

W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9347724	A1	19940214	AU 1993-47724		19930713
US 5498605	A	19960312	US 1994-278704		19940721
PRIORITY APPLN. INFO.:			US 1992-914428	A	19920715
			WO 1993-US6590	W	19930713

OTHER SOURCE(S): MARPAT 122:106395
GI



I

AB The adenosine derivs., e.g. I, wherein at least one of R1-R6 is a sulfohydrocarbon radical, the remaining R groups are non-sulfohydrocarbon radicals, and W is -OCH2-, -NHCH2-, -SCH2-, or -NH(CO)-. Thus, 6-chloropurine riboside reacted with sulfonylamine in BuOH and NEt3 gave N6-p-sulfophenyladenosine. Methods of prepg. such compds., as well as methods of using such compds. to treat **ischemia** or hypoxia in mammals and pharmaceutical compns. contg. such compds. as the active ingredients, are also described. Binding of I with A1 and A2 adenosine receptors at rat brain is reported.

IT **3250-02-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of adenosine sulfohydrocarbon radicals)

RN 3250-02-0 HCAPLUS
CN Adenosine, 2',3'-O-(ethoxymethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L29 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:261298 HCAPLUS
DOCUMENT NUMBER: 123:228787
TITLE: Preparation of adenosine analogs as antihypertensives and antiischemics.
INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: U.S., 25 pp. Cont.-in-part of U.S. Ser. No. 587,884, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5364862	A	19941115	US 1992-955783	19921002
CA 2092305	AA	19920326	CA 1991-2092305	19910925
AT 147074	E	19970115	AT 1991-917927	19910925
ES 2095960	T3	19970301	ES 1991-917927	19910925
SG 80526	A1	20010522	SG 1996-3118	19910925
US 5561134	A	19961001	US 1994-316761	19941003
US 5736554	A	19980407	US 1995-455361	19950531
US 5652366	A	19970729	US 1995-484811	19950607

PRIORITY APPLN. INFO.: US 1990-587884 B2 19900925
US 1992-955783 A2 19921002
US 1994-229882 B2 19940419
US 1994-316761 A1 19941003

OTHER SOURCE(S): MARPAT 123:228787
GI



I





AB Title compds. [I; K = N, NO, CH; Q = CH2, O; T = R2, R1R2NCO, R3OCH2; X = alkylene, cycloalkylene, cycloalkenylene; Y = NR4, O, S; a = 0, 1; Z = Q1, Q2; Z1 = N, CR5, (CH)mCR5, (CH)mN; m = 1, 2; Z2 = N, NR6, O, S; n = 0, 1; R1-R6 = H, alkyl, aryl, heterocyclyl; Ra, Rb = H, OH, alkyl, hydroxyalkyl, alkylmercaptyl, thioalkyl, alkoxy, alkoxyalkyl amino, alkylamino, carboxyl, acyl halo, carbamoyl, alkylcarbamoyl, aryl, heterocyclyl; R', R'' = H, alkyl, aralkyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl; R'R'' = CO, CS, CHORc, CRdRe; Rc, Rd, Re = H, alkyl; RdRe = atoms to form a cycloalkyl ring; with provisos], were prepd. Thus, N6-[trans-2-(thiophen-2-yl)cyclohex-1-yl]adenosine, prepd. from 6-chloropurine riboside and the corresponding amine, at 5 mg/kg orally in rats reduced mean arterial blood pressure and heart rate by 45% and 22%, resp.

IT **165115-09-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of adenosine analogs as antihypertensives and antiischemics)

RN 165115-09-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:621999 HCAPLUS
DOCUMENT NUMBER: 121:221999
TITLE: Preparation of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents
INVENTOR(S): Firestein, Gary Steven; Ugarkar, Bheemarao Ganapatrao; Miller, Leonard Paul; Gruber, Harry Edward; Bullough, David Andrew; Erion, Mark David; Castellino, Angelo John
PATENT ASSIGNEE(S): Gensia, Inc., USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417803	A1	19940818	WO 1994-US1340	19940203
W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9462365	A1	19940829	AU 1994-62365	19940203
EP 682519	A1	19951122	EP 1994-909558	19940203
R: CH, DE, FR, GB, IT, LI				
US 5646128	A	19970708	US 1994-349125	19941201

PRIORITY APPLN. INFO.:
US 1993-14190 A 19930203
US 1989-408707 B2 19890915
US 1990-466979 B2 19900118
US 1991-647117 B2 19910123
US 1991-812916 B2 19911223
US 1994-192645 B1 19940203
WO 1994-US1340 W 19940203

OTHER SOURCE(S): MARPAT 121:221999

GI



I

AB Novel nucleosides I [A = O, CH2, S; B' = (CH2)nB, alkenyl, alkynyl; B = H, alkyl, alkoxy, NH2, alkylamino, etc.; C1, C2 = H, acyl, hydrocarbyloxycarbonyl, or C1C2 = C(:O), .alpha.-alkoxyalkylidene; X = CD; D = H, halo, alkyl, cyano, CO2H, etc.; Y = N, CE; E = H, halo, alkyl, alkylthio; F = alkyl, aryl, halo, cyano, indolyl, pyrrolidinyl, etc.; G = H, halo, alkyl, alkoxy, alkylamino, alkylthio; n = 1-4], prepd. by multistep procedures which are described, selectively inhibit adenosine kinase and are useful in treatment of conditions characterized by an inflammatory response. Such conditions include sepsis, arthritis, autoimmune disease, burns, psoriasis, conjunctivitis, etc. Thus, mice with endotoxemia resulting from injection of Escherichia coli lipopolysaccharide showed a dose-dependent increase in survival in response to i.v. injection of the adenosine kinase inhibitor, 4-amino-1-(5-amino-5-deoxy-1-.beta.-D-ribofuranosyl)-3-bromopyrazolo[3,4-d]pyrimidine-HCl; this effect was antagonized by the adenosine receptor antagonist 8-(p-sulfophenyl)theophylline.

IT **20789-78-0 21950-36-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents)

RN 20789-78-0 HCAPLUS

CN Adenosine, 8-bromo-2',3'-O-(1-methylethylidene)-, 5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 21950-36-7 HCAPLUS
CN Adenosine, 5'-amino-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **144927-45-7P 158077-68-0P 158077-70-4P 158077-71-5P 158077-74-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents)
RN 144927-45-7 HCAPLUS
CN Adenosine, 8-bromo-N-formyl-2',3'-O-(1-methylethylidene)-, 5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158077-68-0 HCAPLUS
CN Adenosine, 5',8-diazido-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158077-70-4 HCAPLUS
CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158077-71-5 HCAPLUS
CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-9-[2,3-O-(1-methylethylidene)-5-O-[(4-methylphenyl)sulfonyl]-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158077-74-8 HCAPLUS
CN Adenosine, 5',8-diazido-5'-deoxy-N-formyl-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:496074 HCAPLUS
DOCUMENT NUMBER: 119:96074
TITLE: Preparation of adenosine derivatives as cardiovascular agents.
INVENTOR(S): Matsuda, Akira; Azebiru, Toichi; Yamaguchi, Toyofumi; Watanabe, Yoko; Miyashita, Takanori
PATENT ASSIGNEE(S): Yamasa Shoyu Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05025195	A2	19930202	JP 1991-202598	19910717
JP 3025559	B2	20000327		

PRIORITY APPLN. INFO.: JP 1990-191285 A1 19900719
JP 1990-218690 A1 19900820
OTHER SOURCE(S): MARPAT 119:96074
GI



I

AB The title compds. [I; R1 = (un)substituted carbamoyl, CO2H,

alkoxycarbonyl, CH2-N3, (un)substituted aminomethyl, etc.; R2 = (hydroxy)alkyl], useful for treatment of brain **ischemia**, heart **ischemia**, and **hypertension**, are prepd. E.g., 2-iodoadenosine was condensed with acetone, the resulting 2',3'-O-isopropylidene deriv. in MeCN-CHCl3 was oxidized with K periodate in H2O, the product was esterified with MeOH, the resulting Me ester was treated with methanolic NH3, the resulting carboxamide was heated with 1-hexyne in DMF contg. Pd(PPh3)2, CuCl, and Et3N, and the resulting 2-(1-hexynyl)-2',3'-isopropylideneadenosine-4'-carboxamide was deprotected to give 2-(1-hexynyl)-adenosine-4'-carboxamide, which had an ED50 of 0.13 .mu.g/Kg in spontaneously **hypertensive** mice.

IT **142102-95-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as cardiovascular agent)

RN 142102-95-2 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[(methylamino)thioxomethyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **141018-25-9P 141018-26-0P 142102-84-9P**
142102-85-0P 142102-86-1P 142102-87-2P
142102-90-7P 142102-91-8P 142102-92-9P
142102-93-0P 142102-94-1P 142103-01-3P
142103-03-5P 142103-04-6P 149037-59-2P
149037-60-5P 149037-61-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for cardiovascular agents)

RN 141018-25-9 HCAPLUS

CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141018-26-0 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-84-9 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-85-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-86-1 HCAPLUS
CN Adenosine, 2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-87-2 HCAPLUS
CN Adenosine, 5'-azido-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-90-7 HCAPLUS
CN Adenosine, 5'-amino-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-91-8 HCAPLUS
CN Adenosine, 5'-deoxy-5'-(formylamino)-2-(1-hexynyl)-2',3'-O-(1-
methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-92-9 HCAPLUS
CN Adenosine, 5'-(acetylamino)-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-93-0 HCAPLUS
CN Adenosine, 5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-5'-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-94-1 HCAPLUS
CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[(methylamino)carbonyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-01-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-03-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-04-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-cyclopropyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149037-59-2 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149037-60-5 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(3-hydroxy-1-propynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149037-61-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(3-hydroxy-1-propynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:234420 HCAPLUS
DOCUMENT NUMBER: 118:234420
TITLE: Adenosine kinase inhibitors
INVENTOR(S): Browne, Clinton E.; Ugarkar, Bheemarao G.; Mullane, Kevin M.; Gruber, Harry E.; Bullough, David A.; Erion, Mark D.; Castellino, Angelo
PATENT ASSIGNEE(S): Gensia Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 87 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 496617	A1	19920729	EP 1992-300580	19920123
EP 496617	B1	19991201		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE

CA 2100863	AA	19920724	CA 1992-2100863	19920121
WO 9212718	A1	19920806	WO 1992-US515	19920121
W: AU, CA, FI, NO				
AU 665184	B2	19951221	AU 1992-13599	19920121
AU 9213599	A1	19920827		
JP 05112595	A2	19930507	JP 1992-10094	19920123
IL 100742	A1	19960618	IL 1992-100742	19920123
AT 187175	E	19991215	AT 1992-300580	19920123
NO 9302628	A	19930923	NO 1993-2628	19930721
NO 180418	B	19970106		
NO 180418	C	19970416		
US 5646128	A	19970708	US 1994-349125	19941201

PRIORITY APPLN. INFO.:

US 1991-647117	A	19910123
US 1991-812916	A	19911223
US 1989-408707	B2	19890915
US 1990-466979	B2	19900118
WO 1992-US515	W	19920121
US 1993-14190	B2	19930203
US 1994-192645	B1	19940203

OTHER SOURCE(S): MARPAT 118:234420

GI



I II

AB Nucleoside analogs I [A = O, CH2, S; B = (un)substituted C1-4 alkyl; C, C1 = H, protective group(s); X = (un)substituted CH; Y = N, (un)substituted CH; F = alkyl, aryl, aralkyl, halogen, (un)substituted NH2, substituted OH or SH, cyano, cyanoalkyl; G = H, halogen, alkyl, alkoxy, alkylamino, alkylthio] were prepd. Thus, the analog II was prepd. from the pyrimidinone via the azide. II has an adenosine kinase-inhibiting ED50 of <10 nM and was effective in improving post-**ischemic** functional recovery in isolated guinea pig heart and in preclin. angina models.

IT **21950-36-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(formylation of)

RN 21950-36-7 HCAPLUS

CN Adenosine, 5'-amino-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **144927-50-4P 144927-52-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deisopropylidenation of)
RN 144927-50-4 HCAPLUS
CN Adenosine, 5'-deoxy-5'-(formylamino)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144927-52-6 HCAPLUS
CN 9H-Purine, 9-[2,3-O-(1-methylethylidene)-5-O-[(4-methylphenyl)sulfonyl]-.beta.-D-ribofuranosyl]-6-(octahydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **144927-45-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with azide)
RN 144927-45-7 HCAPLUS
CN Adenosine, 8-bromo-N-formyl-2',3'-O-(1-methylethylidene)-, 5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **144927-51-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and tosylation of)
RN 144927-51-5 HCAPLUS
CN 9H-Purine, 9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]-6-(octahydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:470205 HCAPLUS
DOCUMENT NUMBER: 117:70205
TITLE: Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity
AUTHOR(S): Homma, Hiroshi; Watanabe, Yohko; Abiru, Toichi; Murayama, Toshihiko; Nomura, Yasuharu; Matsuda, Akira
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan
SOURCE: Journal of Medicinal Chemistry (1992), 35(15), 2881-90
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Chem. modifications of the potent A2 adenosine receptor agonist 2-(hexynyl)adenosine I (R = R1, R2 = OH) (II) at the 5'-position have been carried out to find more potent and selective A2 agonists. These analogs were evaluated for adenosine A1 and A2 receptor binding affinity in rat brain tissues and antihypertensive effects in spontaneously **hypertensive** rats (SHR). Among the series of compds., I (R = R3, R4 = cyclopropyl) had the most potent affinity to the A2 receptor with a Ki of 2.6 nM, which is essentially the same as that of the parent agonist II. However, the most selective agonist for the A2 receptor was 2-(1-hexyn-1-yl)adenosine-5'-N-methyluronamide I (R = R3, R4 = Me) with a Ki of 11 nM and a 162-fold selectivity. Therefore, the A1/A2 selectivity was consequently increased. Other 5'-deoxy-5'-substituted derivs., e.g. I [R = R1, R2 = Cl (III); R = R3, R4 = H, Me, NHMe), were also prepd. Among these nucleosides, no active compds. with potent or selective affinities to both receptors were found except III. Although glycosyl conformations and sugar-puckering of these nucleosides were studied by 1H NMR spectroscopy, there were no pos. correlations between active and inactive agonists. I (R = R3, R4 = H, cyclopropyl) had a potent hypotensive effect at ED30 values of 0.18 and 0.17 .mu.g/kg, resp., upon i.v. administration to anesthetized SHR.

IT **142102-85-0P 142102-90-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and amidation of)

RN 142102-85-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-90-7 HCAPLUS
CN Adenosine, 5'-amino-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142102-86-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and azidolysis of)
RN 142102-86-1 HCAPLUS
CN Adenosine, 2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142102-84-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and coupling of, with hexyne)
RN 142102-84-9 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142102-91-8P 142102-92-9P 142102-93-0P**
142102-94-1P 142102-95-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
RN 142102-91-8 HCAPLUS
CN Adenosine, 5'-deoxy-5'-(formylamino)-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-92-9 HCAPLUS
CN Adenosine, 5'-(acetylamino)-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-93-0 HCAPLUS
CN Adenosine, 5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-5'-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 142102-94-1 HCAPLUS
CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[(methylamino)carbonyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142102-95-2 HCAPLUS
CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[(methylamino)thioxomethyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142102-88-3P 142103-01-3P 142103-02-4P**
142103-03-5P 142103-04-6P 142103-05-7P
142103-06-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deisopropylidenation of)
RN 142102-88-3 HCAPLUS
CN Adenosine, 5'-chloro-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-01-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-02-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-03-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-04-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-cyclopropyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-05-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142103-06-8 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-butyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **141018-26-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and esterification of)
RN 141018-26-0 HCAPLUS
CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142102-87-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., chlorination, and redn. of)
RN 142102-87-2 HCAPLUS
CN Adenosine, 5'-azido-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **141018-25-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., oxidn., and coupling of, with hexyne)
RN 141018-25-9 HCAPLUS
CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:236101 HCAPLUS
DOCUMENT NUMBER: 116:236101
TITLE: Preparation of new adenosine derivatives as cardiovascular agents.
INVENTOR(S): Gadient, Fulvio
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4025879	A1	19920220	DE 1990-4025879	19900816

CA 2064869	AA	19920217	CA 1991-2064869	19910813
WO 9203463	A1	19920305	WO 1991-CH170	19910813
W: AU, CA, CS, FI, HU, JP, KR, PL, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9183032	A1	19920317	AU 1991-83032	19910813
AU 638600	B2	19930701		
EP 496852	A1	19920805	EP 1991-913964	19910813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 60504	A2	19920928	HU 1992-1080	19910813
JP 05502889	T2	19930520	JP 1991-513113	19910813
ZA 9109267	A	19930524	ZA 1991-9267	19911212
RO 110236	B1	19951130	RO 1992-152	19920213
PRIORITY APPLN. INFO.:			DE 1990-4025879 A	19900816
			WO 1991-CH170 A	19910813

OTHER SOURCE(S): MARPAT 116:236101
GI



I

AB The title compds. [I; R1 = H, alkyl, cycloalkyl, Ph, (substituted) phenylalkyl; R2 = H, alkyl, halo, cycloalkyl; R3 = CH2OH, CONHR4; R4 = H, alkyl, cycloalkyl; X = O, S], useful for the treatment of **hypertension**, thrombolism, supraventricular tachycardia, etc. (no data), were prepd. Cyclocondensation of 1'-deoxy-1'-(6-p-methoxyanilino-2-methyl-9-purinyl)-.beta.-D-ribofuranuronic acid N-ethylamide with 1,1'-carbonyldi-1H-imidazole in DMF at room temp. for 5 h gave I [R1 = p-MeOC6H4, R2 = Me, R3 = EtNHCO, X = O].

IT **141426-21-3P 141426-22-4P 141426-23-5P**
141426-24-6P 141426-25-7P 141426-26-8P
141426-27-9P 141426-28-0P 141426-29-1P
141426-30-4P 141426-31-5P 141426-32-6P
141426-33-7P 141426-34-8P 141426-35-9P
141426-36-0P 141426-37-1P 141426-38-2P
141426-39-3P 141426-40-6P 141426-41-7P
141426-42-8P 141426-43-9P 141448-37-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as cardiovascular agent)

RN 141426-21-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-22-4 HCAPLUS

CN Adenosine, N-cyclohexyl-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-23-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclopentylamino)-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-24-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclopentylamino)-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-25-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclohexylamino)-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-26-8 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-27-9 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-(phenylamino)-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-28-0 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-29-1 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-30-4 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclohexylamino)-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-31-5 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[2-methyl-6-[(1-methylethyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-32-6 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[2-methyl-6-(phenylamino)-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-33-7 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-34-8 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-35-9 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-36-0 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-methyl-9H-purin-9-yl)-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-37-1 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-38-2 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-39-3 HCAPLUS
CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-40-6 HCAPLUS
CN Adenosine, N-(4-methoxyphenyl)-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-41-7 HCAPLUS
CN Adenosine, N-(4-chlorophenyl)-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.